Table 1.

Characteristics of Study Population, n = 819 Donor-Recipient Pairs

Median recipient age, y (range)	36.2 (1–62.8)
Year of transplantation - n (%)
1985–1990	76 (9.3%)
1991–1996	484 (59.1%)
1997–2003	259 (31.6%)
Recipient/donor gender, n (%)
Male/male	331 (40.4%)
Male/female	153 (18.7%)
Female/male	173 (21.1%)
Female/female	156 (19.0%)
Unknown	6 (0.7%)
Diagnosis/disease severity*, n (%)/ n
ALL/ high-risk, intermediate-risk	62 (7.6%)/12, 50
AML/ high-risk, intermediate-risk	183 (22.3%)/77, 106
CML/ high-risk, intermediate-risk, low-risk	544 (66.4%)/23, 122, 399
MDS/ high-risk, intermediate-risk	30 (3.7%)/15, 15
Recipient/donor CMV serology, n (%)
Positive/positive	129 (15.8%)
Positive/negative	207 (25.3%)
Negative/positive	102 (12.5%)
Negative/negative	281 (34.3%)
Unknown	100 (12.2%)
Conditioning regimen, n (%)
Total body irradiation-containing	726 (88.6%)
Other	93 (11.4%)
Source of cells - n (%)
Bone marrow	738 (90.1%)
Peripheral blood stem cells	13 (1.6%)
Unknown	68 (8.3%)
T cell depletion, n (%)
Yes	93 (11.4%)
No	726 (88.6%)

ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; CMV, cytomegalovirus.

^*Disease severity categories were defined as low-risk (CML chronic phase), intermediate-risk (CML accelerated phase or blast crisis/remission; acute leukemia transplanted in remission; MDS -refractory anemia); or high-risk (blast crisis CML; acute leukemia transplanted in relapse; MDS other than refractory anemia).